357 related articles for article (PubMed ID: 12430884)
1. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():176-83. PubMed ID: 12430850
[TBL] [Abstract][Full Text] [Related]
4. Critical review on non-myeloablative stem cell transplantation (NST).
Anagnostopoulos A; Giralt S
Crit Rev Oncol Hematol; 2002 Nov; 44(2):175-90. PubMed ID: 12413634
[TBL] [Abstract][Full Text] [Related]
5. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
7. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
8. [Non-myeloablative stem cell transplant].
Shoji N; Mineishi S
Gan To Kagaku Ryoho; 2000 Jun; 27(6):795-800. PubMed ID: 10897204
[TBL] [Abstract][Full Text] [Related]
9. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
Shimoni A; Nagler A
Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
[TBL] [Abstract][Full Text] [Related]
11. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
Handgretinger R; Kurtzberg J; Egeler RM
Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation using non-myeloablative transplant regimens.
Battiwalla M; Barrett J
Best Pract Res Clin Haematol; 2001 Dec; 14(4):701-22. PubMed ID: 11924917
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
[TBL] [Abstract][Full Text] [Related]
14. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
Petersen EJ; Lokhorst HL; Verdonck LF
Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic haemopoietic stem cell transplantation using non-myeloablative conditioning--a local experience.
Leong CF; Cheong SK; Fadilah SA; Ainoon O; Hamidah NH
Med J Malaysia; 2003 Jun; 58(2):229-35. PubMed ID: 14569743
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity allogeneic stem cell transplantation.
Bearman SI
Curr Hematol Rep; 2003 Jul; 2(4):277-86. PubMed ID: 12901324
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Lekakis L; de Lima M
Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
[TBL] [Abstract][Full Text] [Related]
20. Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies.
Busca A; Bruno B; Boccadoro M; Locatelli F; Falda M
Med Sci Monit; 2002 Oct; 8(10):RA221-32. PubMed ID: 12388932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
